Skip to main content

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Publication ,  Journal Article
Sanchez-Perez, LA; Choi, BD; Archer, GE; Cui, X; Flores, C; Johnson, LA; Schmittling, RJ; Snyder, D; Herndon, JE; Bigner, DD; Mitchell, DA ...
Published in: PLoS One
2013

Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be incompatible with immunotherapy. Conversely, it has been proposed that recovery from chemotherapy-induced lymphopenia may actually be exploited to potentiate T-cell responses. Here, we report the first demonstration of TMZ as an immune host-conditioning regimen in an experimental model of brain tumor and examine its impact on antitumor efficacy of a well-characterized peptide vaccine. Our results show that high-dose, myeloablative (MA) TMZ resulted in markedly reduced CD4(+), CD8(+) T-cell and CD4(+)Foxp3(+) TReg counts. Adoptive transfer of naïve CD8(+) T cells and vaccination in this setting led to an approximately 70-fold expansion of antigen-specific CD8(+) T cells over controls. Ex vivo analysis of effector functions revealed significantly enhanced levels of pro-inflammatory cytokine secretion from mice receiving MA TMZ when compared to those treated with a lower lymphodepletive, non-myeloablative (NMA) dose. Importantly, MA TMZ, but not NMA TMZ was uniquely associated with an elevation of endogenous IL-2 serum levels, which we also show was required for optimal T-cell expansion. Accordingly, in a murine model of established intracerebral tumor, vaccination-induced immunity in the setting of MA TMZ-but not lymphodepletive, NMA TMZ-led to significantly prolonged survival. Overall, these results may be used to leverage the side-effects of a clinically-approved chemotherapy and should be considered in future study design of immune-based treatments for brain tumors.

Duke Scholars

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2013

Volume

8

Issue

3

Start / End Page

e59082

Location

United States

Related Subject Headings

  • Vaccines, Subunit
  • Temozolomide
  • Mice, Transgenic
  • Mice
  • Lymphopenia
  • Lymphocyte Depletion
  • Interleukin-2
  • Immunotherapy
  • General Science & Technology
  • Disease Models, Animal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sanchez-Perez, L. A., Choi, B. D., Archer, G. E., Cui, X., Flores, C., Johnson, L. A., … Sampson, J. H. (2013). Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One, 8(3), e59082. https://doi.org/10.1371/journal.pone.0059082
Sanchez-Perez, Luis A., Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, et al. “Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.PLoS One 8, no. 3 (2013): e59082. https://doi.org/10.1371/journal.pone.0059082.
Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, et al. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082.
Sanchez-Perez, Luis A., et al. “Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.PLoS One, vol. 8, no. 3, 2013, p. e59082. Pubmed, doi:10.1371/journal.pone.0059082.
Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, Schmittling RJ, Snyder D, Herndon JE, Bigner DD, Mitchell DA, Sampson JH. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2013

Volume

8

Issue

3

Start / End Page

e59082

Location

United States

Related Subject Headings

  • Vaccines, Subunit
  • Temozolomide
  • Mice, Transgenic
  • Mice
  • Lymphopenia
  • Lymphocyte Depletion
  • Interleukin-2
  • Immunotherapy
  • General Science & Technology
  • Disease Models, Animal